CVS Health Isn't Going To The Dogs
CVS Health's poor 2024 performance was driven by negative macro and micro factors. Investors became too pessimistic about the company's forward prospects. A new CEO is a catalyst. Despite weak 2024 financial results, CVS is likely to begin to rebound in 2025. The company remains free cash flow positive, despite myriad challenges.
CVS Health (CVS) Suffers a Larger Drop Than the General Market: Key Insights
CVS Health (CVS) reachead $51.96 at the closing of the latest trading day, reflecting a -0.35% change compared to its last close.
3 Dividend Stocks at Bargain Levels to Defend Your Portfolio
As 2025 kicks off with a volatile start, many investors are likely feeling the pressure of heightened uncertainty. The S&P 500 and other major indices are down year-to-date, led by sharp declines in tech heavyweights like NVIDIA, which has fallen 13% from its 52-week high set just days ago.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Big Gains Ahead for Medicare Advantage Sellers as Payments Set to Grow
As the largest MA plan sellers, UnitedHealth, Humana and CVS Health collectively account for nearly 60% of the market.
CVS Health stock price rises after Walgreens earnings: is it a buy?
The CVS Health stock price rebounded to $48 on Monday, up 10% from its lowest in December. This rebound continued after the strong Walgreens Boots Alliance earnings, which pushed the stock up almost 50% from its lowest point in 2024.
CVS Health: An Attractive 5.8% Safe Yield For Now
Despite significant headwinds and a 43% stock decline, CVS Health's 5.8% dividend yield remains attractive, with a well-covered payout ratio of 55.9%. CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share and pushing management to revise cash flow guidance down to $9.0 billion. The company saw double-digit revenue growth in two of its three segments, with a slight increase in pharmacy market share to 27.3%.
After Falling More Than 40% in 2024, Can CVS Health Stock Turn Things Around This Year?
CVS Health (CVS 0.50%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in 2024, when its shares nose-dived by 43%.
This Stock Has A 5.81% Yield And Sells For Less Than Book
CVS Health has been named as a Top 25 dividend stock, according the most recent Dividend Channel ''DividendRank'' report. The report noted that among the coverage universe, CVS shares displayed both attractive valuation metrics and strong profitability metrics.
CVS Stock Trades Near 52-Week Low: Should You Buy the Dip?
CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
Legislation slowly wending its way through states and in Washington could mean increased payments to drugstore chains like CVS Health, Walgreens, Walmart and independent pharmacies across the country.
